{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:27:32Z","timestamp":1785814052220,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-40072-x","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T21:46:34Z","timestamp":1771623994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oncofetal chondroitin sulfate positive circulating tumor cells as prognostic biomarkers in early-stage melanoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Judith","family":"Sunzenauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Rammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonhard","family":"St\u00f6ckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Lugmayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Priglinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Pernsteiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Kehrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor Grundtvig","family":"Theander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schr\u00f6cksnadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Webersinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Salanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette \u00d8rskov","family":"Agerb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Sepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"6","key":"40072_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/CMR.0000000000000479","volume":"28","author":"J Lyth","year":"2018","unstructured":"Lyth, J. Conditional recurrence-free survival in patients with primary stage I-II cutaneous malignant melanoma\u2013a population-based study. Melanoma Res. 28(6), 637\u2013640 (2018).","journal-title":"Melanoma Res."},{"issue":"32","key":"40072_CR2","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1200\/JCO.22.00202","volume":"40","author":"C Garbe","year":"2022","unstructured":"Garbe, C. et al. Prognosis of patients with primary melanoma stage I and II according to american joint committee on cancer version 8 validated in two independent cohorts: implications for adjuvant treatment. J. Clin. Oncol. 40(32), 3741\u20133749 (2022).","journal-title":"J. Clin. Oncol."},{"key":"40072_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1200\/JCO.2010.33.3716","volume":"30","author":"J-M Hou","year":"2012","unstructured":"Hou, J.-M. et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J. Clin. Oncol. 30, 525\u2013532 (2012).","journal-title":"J. Clin. Oncol."},{"key":"40072_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41571-023-00781-y","volume":"20","author":"R Lawrence","year":"2023","unstructured":"Lawrence, R., Watters, M., Davies, C. R., Pantel, K. & Lu, Y.-J. Circulating tumour cells for early detection of clinically relevant cancer. Nat. Rev. Clin. Oncol. 20, 487\u2013500 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"40072_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189714","author":"P Kami\u0144ska","year":"2021","unstructured":"Kami\u0144ska, P. et al. Liquid biopsy in melanoma: Significance in diagnostics, prediction and treatment monitoring. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22189714 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"40072_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040960","author":"M Boyer","year":"2020","unstructured":"Boyer, M. et al. Clinical relevance of liquid biopsy in melanoma and merkel cell carcinoma. Cancers https:\/\/doi.org\/10.3390\/cancers12040960 (2020).","journal-title":"Cancers"},{"key":"40072_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1420360","author":"N Slusher","year":"2024","unstructured":"Slusher, N., Jones, N. & Nonaka, T. Liquid biopsy for diagnostic and prognostic evaluation of melanoma. Front. Cell Develop. Biol. https:\/\/doi.org\/10.3389\/fcell.2024.1420360 (2024).","journal-title":"Front. Cell Develop. Biol."},{"key":"40072_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12885-021-08016-y","volume":"21","author":"Y Kiniwa","year":"2021","unstructured":"Kiniwa, Y. et al. Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation. BMC Cancer 21, 287 (2021).","journal-title":"BMC Cancer"},{"key":"40072_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/CMR.0000000000000168","volume":"25","author":"CL Roland","year":"2015","unstructured":"Roland, C. L. et al. Detection of circulating melanoma cells in the blood of melanoma patients. Melanoma Res. 25, 335\u2013341 (2015).","journal-title":"Melanoma Res."},{"key":"40072_CR10","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/lsm.23286","volume":"53","author":"RH Edgar","year":"2021","unstructured":"Edgar, R. H. et al. Predicting metastasis in melanoma by enumerating circulating tumor cells using photoacoustic flow cytometry. Lasers Surg. Med. 53, 578\u2013586 (2021).","journal-title":"Lasers Surg. Med."},{"issue":"8","key":"40072_CR11","doi-asserted-by":"publisher","first-page":"2100083","DOI":"10.1002\/anbr.202100083","volume":"2","author":"YT Kang","year":"2022","unstructured":"Kang, Y. T. et al. Isolation of circulating tumor cells to diagnose melanoma and evaluate the efficacy of surgical resection using melanoma-specific microsystem. Adv. Nanobiomed Res. 2(8), 2100083 (2022).","journal-title":"Adv. Nanobiomed Res."},{"key":"40072_CR12","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1038\/jid.2015.127","volume":"135","author":"ES Gray","year":"2015","unstructured":"Gray, E. S. et al. Circulating melanoma cell subpopulations: Their heterogeneity and differential responses to treatment. J. Invest. Dermatol. 135, 2040\u20132048 (2015).","journal-title":"J. Invest. Dermatol."},{"key":"40072_CR13","doi-asserted-by":"publisher","first-page":"7553","DOI":"10.1038\/s41467-024-51781-0","volume":"15","author":"EE Vidal-Calvo","year":"2024","unstructured":"Vidal-Calvo, E. E. et al. Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate. Nat. Commun. 15, 7553 (2024).","journal-title":"Nat. Commun."},{"key":"40072_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ccell.2015.09.003","volume":"28","author":"A Salanti","year":"2015","unstructured":"Salanti, A. et al. Targeting human cancer by a glycosaminoglycan binding malaria protein. Cancer Cell 28, 500\u2013514 (2015).","journal-title":"Cancer Cell"},{"key":"40072_CR15","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1158\/1541-7786.MCR-16-0103","volume":"14","author":"TM Clausen","year":"2016","unstructured":"Clausen, T. M. et al. Oncofetal chondroitin sulfate glycosaminoglycans are key players in integrin signaling and tumor cell motility. Mol. Cancer Res. 14, 1288\u20131299 (2016).","journal-title":"Mol. Cancer Res."},{"key":"40072_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41698-025-00936-3","volume":"9","author":"C L\u00f8ppke","year":"2025","unstructured":"L\u00f8ppke, C. et al. Multi-cancer detection of circulating tumor cells by targeting oncofetal chondroitin sulfate. NPJ Precis. Oncol. 9, 144 (2025).","journal-title":"NPJ Precis. Oncol."},{"key":"40072_CR17","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/jid.2010.377","volume":"131","author":"V Kupas","year":"2011","unstructured":"Kupas, V. et al. RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. J. Investig. Dermatol. 131, 944\u2013955 (2011).","journal-title":"J. Investig. Dermatol."},{"key":"40072_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/1479-5876-10-192","volume":"10","author":"JB Freeman","year":"2012","unstructured":"Freeman, J. B., Gray, E. S., Millward, M., Pearce, R. & Ziman, M. Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. J. Transl. Med. 10, 192 (2012).","journal-title":"J. Transl. Med."},{"issue":"7","key":"40072_CR19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/cells8070755","volume":"8","author":"L Cayrefourcq","year":"2019","unstructured":"Cayrefourcq, L. et al. S100-EPISPOT: A new tool to detect viable circulating melanoma cells. Cells 8(7), 755 (2019).","journal-title":"Cells"},{"key":"40072_CR20","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-19-2670","volume":"26","author":"A Lucci","year":"2020","unstructured":"Lucci, A. et al. Circulating tumor cells and early relapse in node-positive melanoma. Clin. Cancer Res. 26, 1886\u20131895 (2020).","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"40072_CR21","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.3390\/cancers11111685","volume":"11","author":"K Gorges","year":"2019","unstructured":"Gorges, K. et al. Intra-patient heterogeneity of circulating tumor cells and circulating tumor DNA in Blood of melanoma patients. Cancers 11(11), 1685 (2019).","journal-title":"Cancers"},{"key":"40072_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00963-w","author":"S Guetter","year":"2025","unstructured":"Guetter, S. et al. MCSP+ metastasis founder cells activate immunosuppression early in human melanoma metastatic colonization. Nat. Cancer https:\/\/doi.org\/10.1038\/s43018-025-00963-w (2025).","journal-title":"Nat. Cancer"},{"key":"40072_CR23","doi-asserted-by":"publisher","first-page":"8750","DOI":"10.1038\/s41467-024-52923-0","volume":"15","author":"C Schroeder","year":"2024","unstructured":"Schroeder, C. et al. Tumour-informed liquid biopsies to monitor advanced melanoma patients under immune checkpoint inhibition. Nat. Commun. 15, 8750 (2024).","journal-title":"Nat. Commun."},{"key":"40072_CR24","doi-asserted-by":"publisher","first-page":"42008","DOI":"10.18632\/oncotarget.5788","volume":"6","author":"ES Gray","year":"2015","unstructured":"Gray, E. S. et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 6, 42008\u201342018 (2015).","journal-title":"Oncotarget"},{"key":"40072_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jmoldx.2013.12.004","volume":"16","author":"KL Aung","year":"2014","unstructured":"Aung, K. L. et al. Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system. J. Mol. Diagn. 16, 343\u2013349 (2014).","journal-title":"J. Mol. Diagn."},{"key":"40072_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s40425-019-0659-0","volume":"7","author":"A Forschner","year":"2019","unstructured":"Forschner, A. et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. J. Immunother Cancer 7, 180 (2019).","journal-title":"J. Immunother Cancer"},{"key":"40072_CR27","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","volume":"10","author":"TM Grzywa","year":"2017","unstructured":"Grzywa, T. M., Paskal, W. & W\u0142odarski, P. K. Intratumor and Intertumor Heterogeneity in Melanoma. Transl. Oncol. 10, 956\u2013975 (2017).","journal-title":"Transl. Oncol."},{"key":"40072_CR28","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/s41467-018-05793-2","volume":"9","author":"M\u00d8 Agerb\u00e6k","year":"2018","unstructured":"Agerb\u00e6k, M. \u00d8. et al. The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner. Nat. Commun. 9, 3279 (2018).","journal-title":"Nat. Commun."},{"key":"40072_CR29","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/cyto.b.22236","volume":"108","author":"L Fourdrain","year":"2025","unstructured":"Fourdrain, L. et al. Detection of circulating tumor cells is achieved by flow cytometry in melanoma patients. Cytometry B Clin. Cytom. 108, 312\u2013319 (2025).","journal-title":"Cytometry B Clin. Cytom."},{"key":"40072_CR30","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1200\/JCO.2011.40.0887","volume":"30","author":"S Hoshimoto","year":"2012","unstructured":"Hoshimoto, S. et al. Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J. Clin. Oncol. 30, 3819\u20133826 (2012).","journal-title":"J. Clin. Oncol."},{"key":"40072_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17081281","author":"F Venturi","year":"2025","unstructured":"Venturi, F., Magnaterra, E., Scotti, B., Ferracin, M. & Dika, E. Predictive Factors for sentinel lymph node positivity in melanoma patients: The role of liquid biopsy, microrna and gene expression profile panels. Cancers https:\/\/doi.org\/10.3390\/cancers17081281 (2025).","journal-title":"Cancers"},{"key":"40072_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12102866","volume":"12","author":"M Han","year":"2020","unstructured":"Han, M. et al. In vivo lymphatic circulating tumor cells and progression of metastatic disease. Cancers (Basel) 12, 1\u201318 (2020).","journal-title":"Cancers (Basel)"},{"issue":"224","key":"40072_CR33","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda, C. et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci. Transl. Med. 6(224), 224ra24 (2014).","journal-title":"Sci. Transl. Med."},{"key":"40072_CR34","first-page":"472","volume":"67","author":"JE Gershenwald","year":"2014","unstructured":"Gershenwald, J. E. et al. Melanoma staging: Evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J. Clin. 67, 472\u2013492 (2014).","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"40072_CR35","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.3390\/ijms21072401","volume":"21","author":"NT Sand","year":"2020","unstructured":"Sand, N. T. et al. Optimization of rVAR2-based isolation of cancer cells in blood for building a robust assay for clinical detection of circulating tumor cells. Int. J. Mol. Sci. 21(7), 2401 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"40072_CR36","doi-asserted-by":"publisher","unstructured":"Zakeri, B. et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. https:\/\/doi.org\/10.1073\/pnas.1115485109","DOI":"10.1073\/pnas.1115485109"},{"key":"40072_CR37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"40072_CR38","unstructured":"Ellard, S. et al. ACGS Best Practice Guidelines for Variant Classification in Rare Disease 2020. bioRxiv (2020)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40072-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40072-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40072-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:17:26Z","timestamp":1774527446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40072-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40072"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40072-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.K. is consultant for MSD, Bristol Myers Squibb and Pierre Fabre. The aforementioned functions are unrelated to the research presented in this manuscript. The technology to diagnose cancer through rVAR2 is owned by VarCT Diagnostics through a license from VAR2Pharmaceuticals. A.S., T.G.T., M.\u00d8.A. and P.S. are cofounders of VAR2Pharmaceuticals. The other authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10034"}}